ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference

Company Overview - ProKidney Corp. is a late clinical-stage biotech company focused on developing a first-in-class cell therapy candidate for chronic kidney disease (CKD) [1][2] - The company was founded in 2015 and has a decade of research behind its innovations in cellular therapy [2] Product Information - ProKidney's lead product candidate, rilparencel (also known as REACT®), is an autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies [2] - Rilparencel aims to preserve kidney function in diabetic patients at high risk of kidney failure and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA [2] Upcoming Events - ProKidney's management team will participate in two healthcare conferences in December 2024: - Evercore HealthCONx Conference on December 3, 2024, at 8:45 am ET in a fireside chat format [1] - Citi Global Healthcare Conference on December 4, 2024, featuring one-on-one meetings [1] - The live webcast for the Evercore fireside chat will be available on ProKidney's website [1]